FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2530000047> ?p ?o ?g. }

• W2530000047 abstract "Abstract Despite improvements in the treatment of adults with acute lymphoblastic leukemia (ALL) during the last decade, most patients will relapse and ultimately die of disease. Although some factors that affect risk of disease and treatment outcome are known, our ability to predict response and tailor treatments is far from perfect. In particular, we observed that the majority of the ALL patients treated at our large public hospital in Houston, TX were Hispanic. In order to more closely examine this trend and attempt to identify characteristics that would predict risk or therapeutic response, we performed a retrospective analysis of all patients with precursor B-cell ALL, T-cell ALL, and Burkitt lymphoma treated at our hospital over a fifteen year period. One hundred thirteen patients were identified, including sixty-one with precursor B-cell ALL, thirty-two with Burkitt lymphoma, sixteen with T-cell ALL, and four patients with additional features. All patients were treated with HyperCVAD, alternating with methoxtrexate and cytarabine, although some patients had therapeutic modifications because of disease characteristics, particularly in the first course. The median overall survival for all patients was 357 days. Patients with precursor B-cell ALL had the poorest outcome in both overall survival and progression-free survival, and a less favorable outcome than expected from the literature with a 38% two-year survival (95% CI: 54–92%). In contrast, patients with Burkitt lymphoma had an 80% 2-year survival (95% CI: 54%–92%) and those with T-cell ALL had a 63% 2-year survival (95% CI: 32%–83%). The outcomes for Burkitt lymphoma and T-cell ALL are similar to those reported in the literature. Nearly 80% of the patients with precursor B-cell ALL were Hispanic, and most were older than thirty (mean age 36.4 years) with few comorbidities. In contrast, only about 40% of the other high grade leukemia/lymphoma patients were Hispanic, reflecting more closely the racial/ethnic distribution of the population served by the hospital. While our precursor B-cell ALL patients were predominantly Hispanic, there was no statistical difference in overall survival or progression-free survival for Hispanic versus non-Hispanic patients. Hispanic patients with pre-B ALL had a 38% 2-year survival (95% CI: 20%–55%) while non- Hispanic patients had a 41% 2-year survival (95% CI: 12%–69%). Patients younger than thirty with precursor B-cell ALL had a statistically significant survival benefit compared to older patients. Fourteen patients (22.6%) with precursor B-cell ALL had a white blood cell count greater than 50,000, and these patients had significantly poorer outcomes. There was no correlation between cytogenetic abnormalities and outcome; however, very few patients were found to harbor the 9:22 translocation. There was a high incidence of CD20 positivity (55.7%) in patients with precursor B-cell ALL; however, there was no statistically significant correlation with overall survival or progression-free survival. Thus in our multiethnic patient population, patients with precursor B-cell ALL had significantly poorer outcomes than those reported in the literature, while patients with T-cell ALL or Burkitt lymphoma had outcomes to those reported in the literature using the identical chemotherapy regimen. The older age of the precursor B-cell ALL patients may have contributed to this poorer outcome. As noted above, our precursor B-cell ALL patients were predominately Hispanic as compared to the other leukemia patients we studied. Although Hispanic ethnicity did not clearly contribute to outcome, risk of developing precursor B-cell ALL appears to be greater in the Hispanic population." @default.
• W2530000047 created "2016-10-21" @default.
• W2530000047 creator A5004947863 @default.
• W2530000047 creator A5008386087 @default.
• W2530000047 creator A5048547387 @default.
• W2530000047 creator A5068005246 @default.
• W2530000047 creator A5088664989 @default.
• W2530000047 date "2008-11-16" @default.
• W2530000047 modified "2023-09-28" @default.
• W2530000047 title "Risk and Therapeutic Outcomes in a Multiethnic Group of Acute Lymphoblastic Leukemia Patients Treated at a Large Public Hospital" @default.
• W2530000047 doi "https://doi.org/10.1182/blood.v112.11.3938.3938" @default.
• W2530000047 hasPublicationYear "2008" @default.
• W2530000047 type Work @default.
• W2530000047 sameAs 2530000047 @default.
• W2530000047 citedByCount "0" @default.
• W2530000047 crossrefType "journal-article" @default.
• W2530000047 hasAuthorship W2530000047A5004947863 @default.
• W2530000047 hasAuthorship W2530000047A5008386087 @default.
• W2530000047 hasAuthorship W2530000047A5048547387 @default.
• W2530000047 hasAuthorship W2530000047A5068005246 @default.
• W2530000047 hasAuthorship W2530000047A5088664989 @default.
• W2530000047 hasConcept C126322002 @default.
• W2530000047 hasConcept C141071460 @default.
• W2530000047 hasConcept C143998085 @default.
• W2530000047 hasConcept C167135981 @default.
• W2530000047 hasConcept C187212893 @default.
• W2530000047 hasConcept C2778041864 @default.
• W2530000047 hasConcept C2778461978 @default.
• W2530000047 hasConcept C2778913318 @default.
• W2530000047 hasConcept C2779134260 @default.
• W2530000047 hasConcept C2779338263 @default.
• W2530000047 hasConcept C2781107101 @default.
• W2530000047 hasConcept C2909962599 @default.
• W2530000047 hasConcept C71924100 @default.
• W2530000047 hasConceptScore W2530000047C126322002 @default.
• W2530000047 hasConceptScore W2530000047C141071460 @default.
• W2530000047 hasConceptScore W2530000047C143998085 @default.
• W2530000047 hasConceptScore W2530000047C167135981 @default.
• W2530000047 hasConceptScore W2530000047C187212893 @default.
• W2530000047 hasConceptScore W2530000047C2778041864 @default.
• W2530000047 hasConceptScore W2530000047C2778461978 @default.
• W2530000047 hasConceptScore W2530000047C2778913318 @default.
• W2530000047 hasConceptScore W2530000047C2779134260 @default.
• W2530000047 hasConceptScore W2530000047C2779338263 @default.
• W2530000047 hasConceptScore W2530000047C2781107101 @default.
• W2530000047 hasConceptScore W2530000047C2909962599 @default.
• W2530000047 hasConceptScore W2530000047C71924100 @default.
• W2530000047 hasLocation W25300000471 @default.
• W2530000047 hasOpenAccess W2530000047 @default.
• W2530000047 hasPrimaryLocation W25300000471 @default.
• W2530000047 hasRelatedWork W1572386463 @default.
• W2530000047 hasRelatedWork W1834277939 @default.
• W2530000047 hasRelatedWork W18966879 @default.
• W2530000047 hasRelatedWork W2021721851 @default.
• W2530000047 hasRelatedWork W2092502877 @default.
• W2530000047 hasRelatedWork W2539304549 @default.
• W2530000047 hasRelatedWork W2546446541 @default.
• W2530000047 hasRelatedWork W2554160400 @default.
• W2530000047 hasRelatedWork W2556857497 @default.
• W2530000047 hasRelatedWork W2560566133 @default.
• W2530000047 hasRelatedWork W2576634252 @default.
• W2530000047 hasRelatedWork W2588563183 @default.
• W2530000047 hasRelatedWork W2783494686 @default.
• W2530000047 hasRelatedWork W2934396069 @default.
• W2530000047 hasRelatedWork W2980012658 @default.
• W2530000047 hasRelatedWork W2992713422 @default.
• W2530000047 hasRelatedWork W2993667630 @default.
• W2530000047 hasRelatedWork W3031228654 @default.
• W2530000047 hasRelatedWork W3175879618 @default.
• W2530000047 hasRelatedWork W3214489597 @default.
• W2530000047 isParatext "false" @default.
• W2530000047 isRetracted "false" @default.
• W2530000047 magId "2530000047" @default.
• W2530000047 workType "article" @default.